Q Biomed Inc. Announces FDA Filing for Approval of a New Manufacturing Facility for Non-Opioid Strontium Chloride SR89 Injection USP for Relief of Cancer Bone Pain

NEW YORK, March 16, 2018 -- (Healthcare Sales & Marketing Network) -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, and Bio-Nucleonics, licensor of Strontium 89 Chloride, announce submission of a regulator... Biopharmaceuticals, Oncology, FDA Q Biomed, Strontium 89 Chloride, Bone Pain
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news